LNTH-2401

N/A

Report date: 2025/11/19 17:58:13
NME

Base Information

Drug NameLNTH-2401
Drug Alias Name68Ga-DOTA-4-amino-1-carboxymethyl-piperidine-DPhe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2[(68)Ga]-labelled bombesin[68GA]DOTA-4-AMINO-1-CARBOXYMETHYLPIPERIDINE-D-PHE-GLN-TRP-ALA-VAL-GLY-HIS-STA-LEU-NH2Bombesin (68Ga) labelledGallium-68 RM2 +[12] 
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionGastrin releasing peptide receptor bindersPositron-emission tomography enhancers
TargetsGastrin releasing peptide receptor
Therapy Area/IndicationsProstatic NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustriaUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of BernBayer AGUniversitaetsspitals Basel
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLantheus Holdings IncNational Institutes Of HealthLife Molecular Imaging Ltd +[7] 
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A